Mark Feinberg
Directeur Général chez International AIDS Vaccine Initiative, Inc.
Profil
Mark Feinberg currently works at International AIDS Vaccine Initiative, Inc., as President, Chief Executive Officer & Director and Global HIV Vaccine Enterprise, as Director.
Postes actifs de Mark Feinberg
| Sociétés | Poste | Début |
|---|---|---|
International AIDS Vaccine Initiative, Inc.
 International AIDS Vaccine Initiative, Inc. Pharmaceuticals: MajorHealth Technology International AIDS Vaccine Initiative, Inc. researches and develops to prevent HIV infection and AIDS. It researches and develops vaccine candidates, conducts policy analyses, and serves as an advocate for the field with offices in Africa, India, and Europe. The firm's HIV research and development focuses on three strategies: the design of vaccine immunogens capable of inducing specialized proteins known as broadly neutralizing antibodies, the optimization and development of these antibodies as prevention products, and the development of replicating viral vectors and mRNA. The company was founded in 1996 by Seth Berkley and Lee C. Smith and is headquartered in New York, NY. | Directeur Général | - |
Global HIV Vaccine Enterprise
 Global HIV Vaccine Enterprise Miscellaneous Commercial ServicesCommercial Services Global HIV Vaccine Enterprise engages in the development of preventive HIV vaccines. The company was founded in June 2003 and is headquartered in New York, NY. | Directeur/Membre du Conseil | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
International AIDS Vaccine Initiative, Inc.
International AIDS Vaccine Initiative, Inc. Pharmaceuticals: MajorHealth Technology International AIDS Vaccine Initiative, Inc. researches and develops to prevent HIV infection and AIDS. It researches and develops vaccine candidates, conducts policy analyses, and serves as an advocate for the field with offices in Africa, India, and Europe. The firm's HIV research and development focuses on three strategies: the design of vaccine immunogens capable of inducing specialized proteins known as broadly neutralizing antibodies, the optimization and development of these antibodies as prevention products, and the development of replicating viral vectors and mRNA. The company was founded in 1996 by Seth Berkley and Lee C. Smith and is headquartered in New York, NY. | Health Technology |
Global HIV Vaccine Enterprise
Global HIV Vaccine Enterprise Miscellaneous Commercial ServicesCommercial Services Global HIV Vaccine Enterprise engages in the development of preventive HIV vaccines. The company was founded in June 2003 and is headquartered in New York, NY. | Commercial Services |